1Briel M, Nordmann A J, Bucher HC. Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Curr Opin Lipidol,2005 ,16 :601-605.
2Vasudevan AR, Hasmin YS,Jones PH. Safety of statins: effects on muscle and the liver. Cleve Clin J Med ,2005 ,72 :996-1001.
3Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol, 2004,94 : 30F-34F.
4Perger L, Kohler M, Fattinger K, et al, Fatal liver failure with atorvastatin. J Hepatol,2003,39 : 1095-1097.
5Farmer JA, Torre-AmioneG. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf,2000,23 : 197-213.
6Pfeffer MA, Keech A, Sacks FM. Safety and tolerability of pravastatin in long-term clinical trials:prospective Pravastatin Pooling(PPP) Project.Circulation, 2002,105 : 2341-2346.
7Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet, 2002,360 : 7-22.
8Shepherd J,Hunninghake DB ,Stein EA ,et al. Safety of rouvastatin. Am J Cardiol 2004,94:882-888.
9Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatoxicity. Gastroenterology,2004,126 : 1287 -1292.
10Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease : the most common cause of abnormal liver enzymes in the US population.Gastroenterology,2001,120 (S) : A65.
